IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis (IONS) and AstraZeneca (AZN) presented full data from a failed trial of Wainua for transthyretin amyloid cardiomyopathy (ATTR-CM). Jefferies sees neutral to negative implications for Alnylam (ALNY), which is developing similar drugs. ALNY shares closed flat, IONS down 2%, and AZN down 1% on Friday. The trial missed its primary goal, raising doubts about ALNY's TTR business.
How this was made
The 30-second read
Why it matters
The neutral to negative read‑through suggests silencing may not add value over stabilizers, affecting pipeline valuations.
Market read
First full data release from a pivotal ATTR‑CM trial, causing immediate price moves in three biotech stocks.
What to watch
Potential for future combination therapies and the existing approved indication for nerve damage could sustain revenue.
Background
The CARDIO‑TTRansform trial was the largest ATTR‑CM study to date, testing eplontersen (Wainua) versus placebo.
Ticker impact
Alnylam shares fell up to 5% after full data from the failed cardiomyopathy trial involving Ionis and AstraZeneca were released.
downward pressure on ALNY price in the short term
The trial missed its primary endpoint and analysts view the result as a setback for Alnylam's pipeline.
Ionis closed down 2% after the full results of its co‑developed eplontersen (Wainua) trial were disclosed.
moderate downside for IONS
Trial data was largely as expected but failed to show statistical significance, dampening outlook.
AstraZeneca's U.S. shares slipped about 1% after the trial data were presented.
slight short‑term pressure on AZN
Even though the impact is smaller, the trial outcome reflects on the co‑development partner.
Market effects
TTR biotech sector faces heightened scrutiny; other silencing approaches may be re‑evaluated.
US biotech stocks could see modest pullback following the news.
Limited to companies with TTR programs; broader market impact minimal.
Counterpoint
The data were largely as expected; investors may view the dip as a buying opportunity if long‑term pipeline remains strong.
Key entities
- CompanyAlnylam Pharmaceuticals
Biotech developing TTR silencing therapies.
- CompanyIonis Pharmaceuticals
Co‑developer of eplontersen.
- CompanyAstraZeneca
Partner in eplontersen development.
